Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): final overall survival (OS) results from a phase III randomized study including adjustment for crossover.
Authors
Raymond, ENiccoli, P
Castellano, D
Valle, Juan W
Hammel, P
Raoul, J
Vinik, A
Bang, Y
Lee, S
Borbath, I
Lombard-Bohas, C
Metrakos, P
Smith, D
Chen, J
Seitz, J
Patyna, S
Lu, D
Ishak, J
Faivre, S
Ruszniewski, P
Affiliation
Beaujon Hospital, Clichy, FranceIssue Date
2016